Fenwick Represents Atara Biotherapeutics in Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Fenwick represented Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, in its expanded partnership with Pierre Fabre Laboratories for the U.S. and remaining global commercial markets for tab-cel for up to $640 million and significant double-digit tiered royalties on net sales.

Under the terms of the agreement, Pierre Fabre Laboratories has agreed to reimburse Atara for expected tab-cel global development costs through Biologics License Application (BLA) transfer, and purchase current and future tab-cel inventory through the BLA transfer date. Near-term payments to Atara include approximately $30 million in cash upfront and initial inventory purchase at closing, as well $100 million in potential regulatory milestones through BLA approval. More information about the partnership can be obtained from the announcement.

The Fenwick transaction team was led by Life Sciences Transactions partner Stefano Quintini and included associates Jennifer Yoon and Catherine Kim, and Regulatory partner Mark Ostrau.​​